The global biologics manufacturing sector is forecast to more than double in value over the next decade, according to new data from ResearchAndMarkets.com.
In its latest report, “Global Biologics Contract Manufacturing Market – Industry Trends and Global Forecasts to 2035,”ResearchAndMarkets projects the biologics contract manufacturing market will grow from USD 23.8 billion in 2025 to USD 55 billion by 2035, at a compound annual growth rate of 8.8 per cent.
The study found more than 305 contract manufacturing organisations (CMOs) are currently engaged in biologics production, with most providing full-scale manufacturing services.
“An increasing number of biopharmaceutical developers are relying on contract manufacturers for comprehensive solutions, encompassing bioprocess development and optimisation,” the report stated.
ResearchAndMarkets noted that mammalian cell-based expression systems are the most commonly used in biologics manufacturing, driven by the growing demand for complex products such as monoclonal antibodies, vaccines and cell therapies.
According to the report, Asia-Pacific has also emerged as a key region for manufacturing expansion, with several CMOs establishing or upgrading facilities to meet global demand.
The report highlighted more than 135 mergers and acquisitions and 695 collaboration deals among biologics CMOs in recent years, alongside over USD 7.5 billion in funding investments.
Moreover, the report cautioned that biologics manufacturing is highly capital-intensive and technically demanding, requiring specialised equipment, expertise and strict regulatory compliance.
“With the growing pipeline of biologics and the increased preference for outsourcing manufacturing operations, the biologics CMOs market is anticipated to witness steady growth in the years ahead,” ResearchAndMarkets concluded.
